Investigational Drug Information for ENMD-1198
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug ENMD-1198?
ENMD-1198 is an investigational drug.
There have been 8 clinical trials for ENMD-1198.
The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2010.
The most common disease conditions in clinical trials are Carcinoma, Neoplasms, and Breast Neoplasms. The leading clinical trial sponsors are CASI Pharmaceuticals, Inc., University Health Network, Toronto, and Indiana University Melvin and Bren Simon Cancer Center.
Summary for ENMD-1198
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 56 |
WIPO Patent Applications | 27 |
Japanese Patent Applications | 33 |
Clinical Trial Progress | Phase 2 (2010-04-01) |
Vendors | 13 |
Recent Clinical Trials for ENMD-1198
Title | Sponsor | Phase |
---|---|---|
A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma | CASI Pharmaceuticals, Inc. | Phase 2 |
A Study of ENMD-2076 in Ovarian Clear Cell Cancers | University Health Network, Toronto | Phase 2 |
Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma | University Health Network, Toronto | Phase 2 |
Clinical Trial Summary for ENMD-1198
Top disease conditions for ENMD-1198
Top clinical trial sponsors for ENMD-1198
US Patents for ENMD-1198
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |